Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis

• Published in: BMC cancer Vol. 23; no. 1; pp. 107 - 17
• Main Authors: Chen, Xiu, Wen, Qinglian, Kou, Liqiu, Xie, Xiaolu, Li, Jun, Li, Yaling
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 31.01.2023; BioMed Central; BMC
• Subjects: Adenosine triphosphatase; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Ataxia; Bias; Blood pressure; Cancer; Cancer patients; Cancer therapies; Care and treatment; Cell cycle; Clinical trials; Collaboration; Development and progression; Diagnosis; DNA damage; DNA repair; Dosage and administration; Drug therapy; Drugs; Health aspects; Humans; Hypertension; Hypertension - chemically induced; Hypertension - drug therapy; Hypertension - epidemiology; Incidence; Kinases; Meta-analysis; Monosaccharides; Neoplasms - drug therapy; Niraparib; Olaparib; Ovarian cancer; PARP inhibitors; Patients; Phthalazines - pharmacology; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - adverse effects; Prevention; Risk factors; Software; Sugars; Targeted cancer therapy; China; Hypertension; Niraparib; Olaparib; PARP inhibitors; Meta-analysis

To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians. We used R software to conduct a meta-analysis of phase II/III randomized controlled trials (RCT) on PARP inhibito...